philip mccarthy roswell park

1:30:44

mPatient Radio: Dr. Phillip McCarthy, Roswell Park Cancer Institute

1:05:27

Myeloma Crowd Radio: Dr. Philip McCarthy, Roswell Park Cancer Institute

0:00:31

'Just One Day With Us' with Dr. Philip McCarthy

0:00:27

Meet Dr. Philip McCarthy

0:04:37

Dr. Philip McCarthy discusses Roswell Park Comprehensive Cancer Center's clinical trials for myeloma

0:05:11

Do myeloma cells get included in the stem cell collection and infusion during ASCT? #myeloma

0:01:40

Dr McCarthy on Neutrophil Activity in Multiple Myeloma

0:02:12

Philip McCarthy: COSTEM highlights

0:05:41

What is the New R-ISS for Multiple Myeloma and Should I Be Using it?

0:01:30

ASH 2018: CAR-T Trials Open at Roswell Park Juno and Early 2019

0:28:31

MCRT Buffalo 2018: Myeloma Transplant and Maintenance, Dr. Philip McCarthy

0:03:36

Prof. Philip McCarthy | ASH 17 | Take home messages for transplant-eligible MM patients

0:01:13

Roswell Park Comprehensive Cancer Center - Patient Education Highlights

0:01:00

Dr Philip McCarthy

0:02:01

Who is Eligible for an Allogeneic Transplant?

0:02:52

The evolving role of maintenance therapy post-ASCT in MM

0:25:00

MCRT Buffalo 2018: Myeloma Maintenance and Future Therapies, Dr. Philip McCarthy

0:01:45

How long should my patients be on maintenance therapy?

0:03:10

Should maintenance therapy after autograft be limited?

0:03:38

What is the Difference Between Autologous and Allogeneic Transplant?

0:01:41

Why Roswell Park for Allogeneic and Autologous Transplant?

0:02:18

REVLIMID (Lenalidomide) Maintenance Therapy Approved for Multiple Myeloma Patients

0:01:07

Toxicities Associated With Lenalidomide for Multiple Myeloma

0:04:02

Treatment-free intervals: what is best for patients?